To compare lesion detectability of I-123 MIBG scintigraphy with that of high-dose I-131 MIBG and to evaluate incremental benefit of SPECT/CT over planar image for the detection and localization of the lesions in patients with I-131 MIBG therapy for malignant pheochromocytoma/ paraganglioma and neuroblastoma. Materials and Methods: We retrospectively investigated 16 patients with malignant pheochromocytoma/paraganglioma and neuroblastoma, who were referred for I-131 MIBG therapy. We investigated the lesion detectability in 10 pairs of I-123 and high-dose I-131 MIBG studies of the same patient, obtained within 2 weeks. In 31 studies of I-123 MIBG scintigraphy in 16 patients and 17 studies of high-dose I-131 MIBG scintigraphy in 12 patients, we compared planar and SPECT/CT images for the lesion detectability and localization. Results: The number of lesions detected by I-123 MIBG planer image and SPECT/CT and high-dose planer I-131 MIBG and SPECT/CT were 3.0 and 3.7, 7.3 and 7.7 per study, respectively. SPECT/CT images provided additional diagnostic information over planar images in 25 studies (81%) of 12 patients (75%) in I-123 MIBG scintigraphy and in 9 studies (53%) of 9 patients (75%) in high-dose I-131 MIBG scintigraphy. Conclusion: Post-therapy high-dose I-131 MIBG scintigraphy is superior to I-123 MIBG scintigraphy in lesion detectability even in comparison with I-123 MIBG SPECT/CT images and high-dose I-131 MIBG planar images in patients with malignant neuroendocrine tumors. SPECT/CT images are helpful for accurate identification of anatomic localization compared with planar images.
M etaiodobenzylguanidine (MIBG) is a guanethidine derivative resembling the neurotransmitter norepinephrine in chemical structure. Therefore, showing the similar performance as norepinephrine, MIBG is taken up by the norepinephrine transporter (uptake 1) or passive diffusion, and stored in chromaffin deposit granules or neurosecretory granules in tissues derived from sympathetic nervous system. 1, 2 In this mechanism, MIBG accumulates in tumors originated from neural crests.
Pheochromocytoma/paraganglioma and neuroblastoma are the representative neuroendocrine neoplasms showing intense MIBG accumulation. Pheochromocytoma/paraganglioma is a rare tumor which arises from chromaffin cells of the adrenal medulla/ extra-adrenal sympathetic ganglia. It is reported that approximately 10% of pheochromocytoma and up to 40% of paraganglioma are malignant. 3, 4 Neuroblastoma is one of the most common tumor derived from the embryonal sympathetic nervous system in children. Approximately 30% of neuroblastoma originate from the adrenal medulla and the rest arise from anywhere extra-adrenal sympathetic nervous system. 5, 6 Malignant pheochromocytoma/paraganglioma and neuroblastoma usually matastasize to the bones, liver, lung, and lymph nodes in early times.
Since I-131 labeled MIBG scintigraphy for pheochromocytoma was reported in 1981, I-131 and I-123 labeled MIBG scintigraphy has been widely used as an excellent functional imaging modality for detection of the lesions in patients with neuroendocrine tumors. [7] [8] [9] MIBG scintigraphy is also useful for detection of the recurrent or metastatic lesions in patients with malignant pheochromocytoma/paraganglioma and neuroblastoma, although it is reported that the sensitivity in detecting extra-adrenal or malignant tumors is less than that in adrenal or benign tumors. 10 -13 In the image quality and lesion detectability, I-123 MIBG image is superior to I-131 MIBG with diagnostic low radioactive dose, 14, 15 because the ␥-ray energy of I-123 (159 keV) is more suitable for scintigraphy compared with that of I-131 (364 keV). In addition to low-dose I-123 MIBG imaging, high-dose I-131 MIBG imaging is possible in patients who underwent I-131 MIBG internal radiation therapy, which is a precious option of the systemic treatments especially in those patients who have irresectable or multiple metastatic lesions. A case report demonstrated that post-therapeutic high-dose I-131 MIBG scintigraphy detected more lesions than low-dose diagnostic I-123 MIBG scintigraphy in a patient underwent I-131 MIBG therapy. 16 Similar findings were observed in the diagnostic I-123 and high-dose post-treatment I-131 scintigraphy in thyroid cancer. 17 Accurate identification of anatomic localization of the lesions is important to perform I-131 MIBG therapy safely. However, it is difficult to identify accurate anatomic localization of the lesions in the conventional planar image. Comparing SPECT with CT or MRI image side-by-side or SPECT-CT or MRI fusion image by use of software has contributed to the precise definition of the localization to some degree. 18 -20 Recently, integrated SPECT/CT fusion system which acquires the dual modality in the same session provides more additional information for characterization and localization of the lesions in various neuroendocrine tumors. [21] [22] [23] [24] [25] [26] The aim of this study was to compare lesion detectability of the I-123 MIBG scintigraphy with that of high-dose I-131 MIBG scintigraphy and to evaluate incremental benefit of I-123 MIBG and high-dose I-131 MIBG SPECT/CT over conventional planar image for the detection and localization of the lesions in patients who underwent I-131 MIBG therapy for malignant pheochromocytoma/ paraganglioma and neuroblastoma.
MATERIALS AND METHODS

Patients
We retrospectively investigated 16 patients with malignant pheochromocytoma/paraganglioma and neuroblastoma, who were referred for I-131 MIBG therapy in our institute and underwent I-123 MIBG (111 MBq ͓3 mCi͔) and/or high-dose I-131 MIBG (3.7-14.8 GBq ͓100 -400 mCi͔) scintigraphy from June 2008 to August 2009 (5 males and 3 females with malignant pheochromocytoma/paraganglioma, mean age 54 years ͓range, 36 -69 years͔; 3 males and 5 females with neuroblastoma, mean age 8.8 years ͓range, 7-13 years͔ ( Table 1) . Thirty-one studies of I-123 MIBG scintigra-phy were obtained in 16 patients and 17 studies of high-dose I-131 MIBG scintigraphy were acquired in 12 patients.
I-123 MIBG Scintigraphy With Diagnostic Low-Radioactive Dose
I-123 MIBG scintigraphy was performed after intravenous injection of 111 MBq (3 mCi) of radiopharmaceutical for all patients, using a dual-head gamma camera equipped with a lowintermediate energy collimator and a 5/8 inch NaI crystal, which was combined to a low-dose spiral CT by the same gantry (Symbia, Siemens Medical Solutions). Whole-body planar images were acquired at 6 and 24 hours after I-123 MIBG injection at scanning speeds of 15 cm/min. Following planar imaging after 6 hours of tracer injection, SPECT images were obtained to cover the areas suspected of abnormal tracer accumulations in whole-body planar images. SPECT data were acquired from 60 projections (20 seconds per view) with 128 ϫ 128 matrix and reconstructed using a 3-dimensional iterative algorithm, ordered-subsets expectation maximization. As soon as SPECT data acquisition was finished, CT transmission scans for tomography were performed. SPECT and CT data were analyzed and coregistered using an e-soft workstation.
I-131 MIBG Therapy and Scintigraphy With Post-Therapy High-Radioactive Dose
I-131 MIBG therapy was administered to the patients who were considered to have beneficial therapeutic effects through the findings of pretherapy I-123 MIBG scintigraphy. 3.7-14.8 GBq (100 -400 mCi) of I-131 MIBG was injected intravenously through fixed peripheral venous lines for about an hour, using lead-shielded infusion pump. Vital signs were monitored for more than 6 hours from the beginning of I-131 MIBG administration. I-131 MIBG planar and SPECT/CT images were acquired 3 days later in the same way as I-123 MIBG scintigraphy, except for the use of collimator (high-energy).
Image Interpretation
At first, I-123 or I-131 MIBG planar images were evaluated by 2 experienced nuclear medicine physicians, who were blinded to the findings of the other imaging modalities. They were asked to interpret all focal uptakes, except for physiological accumulation, as M  pheo  2  400  3  2  2  37  F  pheo  2  400  3  2  3  60  F  pheo  2  400  3  2  4  63  M  para  1  200  3  1  5  66  M  pheo  3  600  2  0  6  54  F  para  1  200  3  1  7  47  M  pheo  4  1360  2 abnormal lesions and to define their anatomic locations. Diffuse accumulation at nasal cavity, salivary glands, thyroid, myocardium, liver, and bladder was considered as physiological uptake. When their interpretations were discordant, consensus was obtained after a conference. Then, SPECT/CT images were assessed by them independently with planar images and they were required to re-evaluate the anatomic location of the lesions found in planar images and indicate new lesions. The findings suspected of metastasis in CT images alone were not included in new lesions if they did not accompany MIBG accumulation. Consensus was acquired in the same way as planar image if their interpretation was discordant.
Data Analysis
In comparison of diagnostic value of I-123 MIBG and highdose I-131 MIBG scintigraphy, we investigated the difference of the number of detected lesions in 10 pairs of I-123 and high-dose I-131 MIBG studies of the same patient that were obtained within 2 weeks. In the evaluation of incremental diagnostic value of SPECT/CT images over planar images with I-123 MIBG and high-dose I-131 MIBG, we performed comparative analysis between planar and SPECT/CT images in all patients.
RESULTS
In I-123 MIBG scintigraphy, a total of 145 and 155 abnormal uptakes were pointed out in planar and SPECT/CT images, respectively, in 31 studies of 16 patients. In high-dose I-131 MIBG scintigraphy, a total of 136 and 140 abnormal uptakes were pointed out in planar and SPECT/CT images, respectively, in 17 studies of 12 patients.
In comparison of all 10 pairs of I-123 and high-dose I-131 MIBG studies in the same patient that were obtained within 2 weeks, the lesions detected by I-123 MIBG scintigraphy were 3.0/study in planar image, 3.7/study in SPECT/CT image; and the lesions detected by high-dose I-131 MIBG scintigraphy were 7.3/study in planar image, 7.7/study in SPECT/CT images. The number of detected lesions is summarized in Table 2 .
In all I-123 MIBG SPECT/CT images, 18 new lesions, which had not been pointed out in planar images, were detected in 14 studies (45.2%) of 11 patients (68.8%), but 8 lesions which had been recognized in planar images became undetectable in 4 studies (12.9%) of 2 patients (12.5%). Anatomic locations of 21 lesions in planar image were modified after analysis of SPECT/CT images in 14 studies (45.2%) of 10 patients (62.5%). As a whole, SPECT/CT 0  0  14  neuro  23  18  0  5  3  15  neuro  1  2  1  0  1  16  neuro  1  3  2  0  0  17  para  1  2  1  0  1  18  pheo  2  2  0  0  1  19  neuro  1  1  0  0  0  20  pheo  2  2  0  0  0  21  pheo  1  3  2  0  0  22  pheo  3  3  0  0  0  23  pheo  1  1  0  0  1  24  para  16  16  0  0  2  25  neuro  2  2  1  1  0  26  pheo  3  4  1  0  0  27  pheo  1  1  0  0  0  28  pheo  3  3  0  0  1  29  pheo  1  1  1  1  0  30  para  22  22  0  0  3  31  neuro  15  15  1  1  1  Total  145  155  18  8 Table 3 .
In high-dose I-131 MIBG SPECT/CT images, 6 new lesions were detected in 4 studies (23.5%) of 4 patients (33.3%), but 2 lesions which had been recognized in planar images became obscure in 2 studies (11.8%) of 2 patients (16.7%). Anatomic locations of 17 lesions were altered after the evaluation of SPECT/CT images in 8 studies (47.1%) of 8 patients (66.7%). As a whole, SPECT/CT images provided additional diagnostic information in 9 studies (52.9%) of 9 patients (75.0%) over planar images. The number of the lesions in high-dose I-131 MIBG planar and SPECT/CT imaging is summarized in Table 4 .
Most of the new lesions detected in SPECT/CT were located near the physiological uptake or were overlapped with the physio- logical accumulation. In I-123 MIBG SPECT/CT images, 10 of 18 newly detected lesions by SPECT/CT were overlapped with the physiological accumulation and 1 new lesion was detected as a lymph node, 4 were in bones, and 3 were in lungs. In high-dose I-131 MIBG SPECT/CT images, 4 of 6 newly detected lesions were overlapped with the physiological accumulation and other one lesion was detected as a lymph node and another one was in a bone. All of the lesions turned to be negative in SPECT/CT were suspected to be located in bones in planar images. The representative comparative planar images with I-123 MIBG and high-dose I-131 MIBG of a 10-year-old male patient with neuroblastoma are shown in Figure 1 . A representative case with beneficial I-123 MIBG SPECT/CT over planar image for the detection of the lesion is shown in Figure 2 . A case with beneficial SPECT/CT over planar image for the localization of the abnormal uptake is shown in Figure 3 .
DISCUSSION
I-131 MIBG internal radiation therapy has become popular as a systemic therapy for patients with malignant neuroendocrine tumors such as malignant pheochromocytoma, malignant paraganglioma, and neuroblastoma with metastatic lesions [27] [28] [29] [30] in addition to chemotherapy represented by combined regimen of cyclophosphamide, vincristine, and dacarbazine. 31 For the indication of I-131 MIBG therapy, it is essential to confirm MIBG accumulation to the metastatic lesions and to rule out MIBG accumulation to high-risk sites such as the lesion compressing spinal cord. In our institute, FIGURE 2. A 54-year-old woman with malignant paraganglioma underwent diagnostic I-123 MIBG scintigraphy. In the planar image, it is easy to point out the abnormal accumulation in the lower abdomen (narrow arrow), however, it is difficult to detect the abnormal uptake beside the bladder (wide arrow) because of physiological accumulation in the bladder. In the SPECT/CT, it is easy to detect the abnormal MIBG accumulation corresponding to the nodular lesion in the left side of the bladder.
FIGURE 3.
A 47-year-old woman with malignant pheochromocytoma underwent diagnostic lowdose I-123 MIBG scintigraphy. In the planar image, it is difficult to determine whether the abnormal uptake in the right upper abdomen exists in the right rib or in the liver. In the SPECT/CT, it is proved that the abnormal accumulation exists in the liver. 
